Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis

INDIANAPOLIS, May 9, 2023. Eli Lilly and Company announced today new investigational data for mirikizumab in patients with moderately to severely active ulcerative colitis (UC) that further support the efficacy and safety seen in previous pivotal...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials